H
Halfdan Sorbye
Researcher at Haukeland University Hospital
Publications - 180
Citations - 10160
Halfdan Sorbye is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 41, co-authored 157 publications receiving 8269 citations. Previous affiliations of Halfdan Sorbye include European Organisation for Research and Treatment of Cancer & Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger,Halfdan Sorbye,Bengt Glimelius,Bengt Glimelius,Graeme J. Poston,Peter M. Schlag,Philippe Rougier,Wolf O. Bechstein,John N. Primrose,Euan Walpole,Meg Finch-Jones,Daniel Jaeck,Darius F. Mirza,Rowan W. Parks,Laurence Collette,M. Praet,U. Bethe,Eric Van Cutsem,Werner Scheithauer,Thomas Gruenberger +19 more
TL;DR: In this article, the authors compared the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.
Journal ArticleDOI
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983) : long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger,Halfdan Sorbye,Bengt Glimelius,Graeme J. Poston,Peter M. Schlag,Philippe Rougier,Wolf O. Bechstein,John N. Primrose,Euan Walpole,Meg Finch-Jones,Daniel Jaeck,Darius F. Mirza,Rowan W. Parks,Murielle Mauer,Erik Tanis,Eric Van Cutsem,Werner Scheithauer,Thomas Gruenberger +17 more
TL;DR: Overall survival data after long-term follow-up found no difference in overall survival with the addition of perioperative chemotherapy with FOLFOX4 compared with surgery alone for patients with resectable liver metastases from colorectal cancer, however, the previously observed benefit in PFS means it should remain the reference treatment for this population of patients.
Journal ArticleDOI
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
Halfdan Sorbye,Staffan Welin,Seppo W. Langer,Lene Weber Vestermark,Nanna Holt,Pia Österlund,Svein Dueland,Eva Hofsli,Marianne Grønlie Guren,Katarina Ohrling,Elke Birkemeyer,Espen Thiis-Evensen,Matteo Biagini,Henning Grønbæk,L. M. Soveri,Ingrid Holst Olsen,Birgitte Federspiel,J Assmus,Eva Tiensuu Janson,Ulrich Knigge +19 more
TL;DR: Advanced GI-NEC patients should be considered for chemotherapy treatment without delay, and poor performance status, colorectal primary and elevated platelets and LDH levels were prognostic factors for survival.
Journal ArticleDOI
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Martin Fassnacht,Massimo Terzolo,Bruno Allolio,Eric Baudin,Harm R. Haak,Alfredo Berruti,Staffan Welin,Carmen Schade-Brittinger,André Lacroix,Barbara Jarzab,Halfdan Sorbye,David J. Torpy,Vinzenz Stepan,David E. Schteingart,Wiebke Arlt,Matthias Kroiss,Sophie Leboulleux,Paola Sperone,Anders Sundin,I G C Hermsen,Stefanie Hahner,Holger S. Willenberg,Antoine Tabarin,Marcus Quinkler,Christelle De La Fouchardiere,Martin Schlumberger,Franco Mantero,Dirk Weismann,Felix Beuschlein,Hans Gelderblom,Hanneke Wilmink,Monica Sender,Maureen Edgerly,Werner Kenn,Tito Fojo,Hans-Helge Müller,Britt Skogseid +36 more
TL;DR: Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus Mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival.
Journal ArticleDOI
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Kjell Magne Tveit,Tormod Kyrre Guren,Bengt Glimelius,Per Pfeiffer,Halfdan Sorbye,Seppo Pyrhönen,Fridbjorn Sigurdsson,Elin H. Kure,Tone Ikdahl,Eva Skovlund,Tone Fokstuen,Flemming Hansen,Eva Hofsli,Elke Birkemeyer,Anders Johnsson,Hans Starkhammar,Mette Karen Yilmaz,Nina Keldsen,Anne Berit Erdal,Olav Dajani,Olav Dahl,Thoralf Christoffersen +21 more
TL;DR: Cetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC, and patients with KRAS wild-type tumors did not provide any additional benefit compared with FLOX alone.